Skip to content
10-Q

Quarterly Report

NIKA PHARMACEUTICALS, INC NIKA

0001826466-25-000058

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 13, 2025 1.03B sh
Short Term Debt Q1 2025 · Mar 31, 2025 $269.16K
Short Term Debt Q1 2025 · Dec 31, 2024 $239.16K
Cash And Equivalents Q1 2025 · Mar 31, 2025 $19.14K
Cash And Equivalents Q1 2025 · Dec 31, 2024 $2.08K
Current Liabilities Q1 2025 · Mar 31, 2025 $269.16K
Current Liabilities Q1 2025 · Dec 31, 2024 $239.16K
Total Liabilities Q1 2025 · Mar 31, 2025 $269.16K
Total Liabilities Q1 2025 · Dec 31, 2024 $239.16K
Current Assets Q1 2025 · Mar 31, 2025 $34.99K
Current Assets Q1 2025 · Dec 31, 2024 $17.93K
Total Assets Q1 2025 · Mar 31, 2025 $34.99K
Total Assets Q1 2025 · Dec 31, 2024 $17.93K
Shares Diluted Q1 2025 · Mar 31, 2024 876.09M sh
Operating Cash Flow restated Q1 2025 · Mar 31, 2024 −$84.35K
Stockholders Equity Q1 2025 · Mar 31, 2024 −$224.48K
Stockholders Equity Q1 2025 · Dec 31, 2023 −$82.15K
Eps Diluted Q1 2025 · Mar 31, 2024 $0.00
Eps Basic Q1 2025 · Mar 31, 2024 $0.00
Sga Expense restated Q1 2025 · Mar 31, 2024 $8.45K
Net Income restated Q1 2025 · Mar 31, 2024 −$45.95K
Operating Income restated Q1 2025 · Mar 31, 2024 −$45.95K